Lantheus Holdings, Inc. Business Acquisition, Pro Forma Revenue
Lantheus Holdings, Inc. (LNTH) reported Business Acquisition, Pro Forma Revenue of $350.31 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-23.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2023-02-23
- Lantheus Holdings, Inc. business acquisition, pro forma revenue for the quarter ending 2020-12-31 was $94.15M, a 9.88% decline year-over-year.
- Lantheus Holdings, Inc. business acquisition, pro forma revenue for the quarter ending 2020-09-30 was $88.54M, a 3.11% decline year-over-year.
- Lantheus Holdings, Inc. business acquisition, pro forma revenue for the quarter ending 2019-12-31 was $104.47M.
- Lantheus Holdings, Inc. business acquisition, pro forma revenue for the quarter ending 2019-09-30 was $91.39M.
- Lantheus Holdings, Inc. business acquisition, pro forma revenue for fiscal 2020 was $350.31M, a 8.37% decline from fiscal 2019.
- Lantheus Holdings, Inc. business acquisition, pro forma revenue for fiscal 2019 was $382.32M.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|
| 2020-12-31 | $94.15M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $182.70M derived: sum of 2 quarters · filed 2023-02-23 | $350.31M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $88.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $256.16M 10-Q · filed 2020-11-05 | ||
| 2020-06-30 | $167.62M 10-Q · filed 2021-07-28 | |||
| 2019-12-31 | $104.47M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $195.86M derived: sum of 2 quarters · filed 2022-02-24 | $382.32M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $91.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $277.85M 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $186.46M 10-Q · filed 2020-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |